Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan.
Children
Coronavirus disease 2019
Delta variant of concern
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
10
12
2021
revised:
11
01
2022
accepted:
14
01
2022
pubmed:
26
1
2022
medline:
17
3
2022
entrez:
25
1
2022
Statut:
ppublish
Résumé
Delta variant of concern (VOC) is the current predominant severe acute respiratory coronavirus type 2 strain causing coronavirus disease 2019 (COVID-19); however, information regarding the impact of the Delta VOC on clinical features and outcomes in pediatric patients with COVID-19 is limited. We conducted a retrospective observational study using the data of patients <18 years of age in COVIREGI-JP, the COVID-19 registry in Japan. The patients were divided into two groups according to the timing of enrollment in the registry (pre-Delta VOC era, October 2020 to May 2021; and Delta VOC era, August to October 2021), and the clinical characteristics and outcomes were compared between the two groups. During the study period, 950 and 349 pediatric patients were registered in the pre-Delta VOC and Delta VOC eras, respectively. The median patient age was younger and the proportion of patients with underlying diseases was higher in the Delta VOC era than that in the pre-Delta VOC era (10.0 vs 7.0 years, P < 0.001, and 7.4% [n = 70] vs. 12.6% [n = 44], P = 0.004, respectively). Significantly more patients were admitted to the intensive care unit in the Delta VOC era than in the pre-Delta VOC era (1.4% [ n = 5] vs. 0.1% [n = 1], P = 0.006), but no patient in either group died or required mechanical ventilation or extracorporeal membrane oxygenation throughout the study period, suggesting that the overall outcomes in children with COVID-19 remained favorable even in the Delta VOC era in Japan.
Identifiants
pubmed: 35074258
pii: S1341-321X(22)00022-8
doi: 10.1016/j.jiac.2022.01.009
pmc: PMC8769918
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
591-594Informations de copyright
Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1249-1254
pubmed: 34499628
J Pediatric Infect Dis Soc. 2021 Dec 31;10(12):1097-1100
pubmed: 34487185
Transl Pediatr. 2020 Dec;9(6):873-875
pubmed: 33457311
Clin Infect Dis. 2021 Dec 6;73(11):e3677-e3689
pubmed: 32986793
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Cell Mol Life Sci. 2016 Dec;73(23):4433-4448
pubmed: 27392606